Bank of New York Mellon
OCUL icon

Bank of New York Mellon’s Ocular Therapeutix OCUL Stock Holding History

Bank of New York Mellon’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.43M Buy
553,236
+77,249
+16% +$700K ﹤0.01% 2396
2026
Q1 		$4.03M Sell
475,987
-14,291
-3% -$136K ﹤0.01% 2440
2025
Q4 		$5.95M Buy
490,278
+89,505
+22% +$1.09M ﹤0.01% 2228
2025
Q3 		$4.69M Buy
400,773
+18,464
+5% +$221K ﹤0.01% 2361
2025
Q2 		$3.55M Sell
382,309
-37,184
-9% -$291K ﹤0.01% 2461
2025
Q1 		$3.07M Sell
419,493
-738
-0.2% -$5.67K ﹤0.01% 2460
2024
Q4 		$3.59M Sell
420,231
-4,204
-1% -$41K ﹤0.01% 2465
2024
Q3 		$3.69M Sell
424,435
-71,200
-14% -$587K ﹤0.01% 2446
2024
Q2 		$3.39M Buy
495,635
+164,383
+50% +$1.01M ﹤0.01% 2525
2024
Q1 		$3.01M Buy
331,252
+87,891
+36% +$624K ﹤0.01% 2551
2023
Q4 		$1.09M Buy
243,361
+3,051
+1% +$9.02K ﹤0.01% 3141
2023
Q3 		$755K Sell
240,310
-53,102
-18% -$217K ﹤0.01% 3337
2023
Q2 		$1.51M Buy
293,412
+3,357
+1% +$20K ﹤0.01% 2985
2023
Q1 		$1.53M Buy
290,055
+23,699
+9% +$113K ﹤0.01% 2943
2022
Q4 		$748K Sell
266,356
-4,254
-2% -$14.1K ﹤0.01% 3336
2022
Q3 		$1.12M Buy
270,610
+21,592
+9% +$109K ﹤0.01% 3147
2022
Q2 		$1M Sell
249,018
-14,022
-5% -$53K ﹤0.01% 3211
2022
Q1 		$1.3M Buy
263,040
+1,883
+0.7% +$10.4K ﹤0.01% 3148
2021
Q4 		$1.82M Buy
261,157
+14,820
+6% +$115K ﹤0.01% 3048
2021
Q3 		$2.46M Buy
246,337
+27,832
+13% +$313K ﹤0.01% 2864
2021
Q2 		$3.1M Sell
218,505
-39,412
-15% -$599K ﹤0.01% 2736
2021
Q1 		$4.23M Sell
257,917
-65,394
-20% -$1.26M ﹤0.01% 2518
2020
Q4 		$6.69M Buy
323,311
+135,811
+72% +$2.02M ﹤0.01% 2216
2020
Q3 		$1.43M Buy
187,500
+18,833
+11% +$156K ﹤0.01% 2891
2020
Q2 		$1.41M Buy
168,667
+45,335
+37% +$300K ﹤0.01% 2899
2020
Q1 		$610K Buy
123,332
+3,663
+3% +$18.1K ﹤0.01% 3258
2019
Q4 		$473K Buy
119,669
+7,397
+7% +$25.7K ﹤0.01% 3617
2019
Q3 		$341K Buy
112,272
+6,805
+6% +$30.4K ﹤0.01% 3730
2019
Q2 		$464K Buy
105,467
+2,990
+3% +$11.1K ﹤0.01% 3640
2019
Q1 		$407K Buy
102,477
+3,287
+3% +$13.2K ﹤0.01% 3633
2018
Q4 		$395K Buy
99,190
+4,896
+5% +$27K ﹤0.01% 3597
2018
Q3 		$649K Hold
94,294
– – ﹤0.01% 3510
2018
Q2 		$636K Buy
94,294
+11,276
+14% +$77.5K ﹤0.01% 3504
2018
Q1 		$541K Buy
83,018
+13,699
+20% +$77.1K ﹤0.01% 3555
2017
Q4 		$309K Sell
69,319
-12,267
-15% -$62.7K ﹤0.01% 3790
2017
Q3 		$504K Buy
81,586
+166
+0.2% +$1.07K ﹤0.01% 3582
2017
Q2 		$755K Sell
81,420
-7,316
-8% -$70.8K ﹤0.01% 3411
2017
Q1 		$824K Buy
88,736
+17,679
+25% +$147K ﹤0.01% 3342
2016
Q4 		$595K Sell
71,057
-13,142
-16% -$102K ﹤0.01% 3509
2016
Q3 		$578K Buy
84,199
+28,284
+51% +$172K ﹤0.01% 3462
2016
Q2 		$277K Sell
55,915
-4,832
-8% -$47.9K ﹤0.01% 3772
2016
Q1 		$586K Sell
60,747
-7,084
-10% -$53.7K ﹤0.01% 3359
2015
Q4 		$635K Sell
67,831
-4,893
-7% -$52.8K ﹤0.01% 3422
2015
Q3 		$1.02M Buy
72,724
+18,942
+35% +$381K ﹤0.01% 3175
2015
Q2 		$1.13M Buy
53,782
+32,006
+147% +$793K ﹤0.01% 3265
2015
Q1 		$914K Buy
21,776
+4,488
+26% +$148K ﹤0.01% 3352
2014
Q4 		$407K Buy
17,288
+4,309
+33% +$72.5K ﹤0.01% 3692
2014
Q3 		$195K Buy
+12,979
New +$192K ﹤0.01% 3904

Other funds holding OCUL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Bank of New York Mellon's OCUL Position: Q2 2026 in Review

Bank of New York Mellon increased its Ocular Therapeutix (OCUL) stake by 16% in Q2 2026, buying an estimated $700K and bringing the position to 553,236 shares worth $5.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

Bank of New York Mellon first reported a position in OCUL in Q3 2014 and has held it in 48 quarters since. The position peaked at $6.69M in Q4 2020. 103 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Bank of New York Mellon held 553,236 shares of Ocular Therapeutix worth $5.43M as of Q2 2026.
  • Bank of New York Mellon bought 77,249 Ocular Therapeutix shares in Q2 2026, an estimated $700K.
  • Ocular Therapeutix made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2396 holding.
  • Bank of New York Mellon first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 48 quarters since.
  • Bank of New York Mellon's Ocular Therapeutix position peaked at $6.69M in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.